Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

How the French national authority for health assesses medicines for use in pediatrics.

Archives de pediatrie : organe officiel de la Societe francaise de pediatrie·2024
Same author

[History of pediatric nephrology in France].

Medecine sciences : M/S·2023
Same author

Hemolytic-Uremic Syndrome in Children.

Pediatric clinics of North America·2023
Same author

Outcome of infantile nephropathic cystinosis depends on early intervention, not genotype: A multicenter sibling cohort study.

Journal of inherited metabolic disease·2022
Same author

An international cohort study spanning five decades assessed outcomes of nephropathic cystinosis.

Kidney international·2021
Same author

Association between 25(OH) vitamin D and graft survival in renal transplanted children.

Pediatric transplantation·2020
Same journal

Supporting patients and family members facing treatment choices in chronic kidney disease: What do professionals think of the decision aids used? - Professionals’ views on treatment decision support tools

Nephrologie & therapeutique·2026
Same journal

From Turing to ChatGPT: The origins and transformations of medical artificial intelligence

Nephrologie & therapeutique·2026
Same journal

Analysis of the predictive value of serum Cys-C and IL-6 levels for acute kidney injury in patients with acute respiratory distress syndrome.

Nephrologie & therapeutique·2026
Same journal

Navigating pain in chronic kidney disease: Overcoming inertia!

Nephrologie & therapeutique·2026
Same journal

Kidney health for all: caring for people, protecting the planet1.

Nephrologie & therapeutique·2026
Same journal

When the heart breaks, the kidneys follow: A case of Takotsubo syndrome

Nephrologie & therapeutique·2026
See all related articles

Related Experiment Video

Updated: May 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

[Immunosuppressive treatment].

Patrick Niaudet1

  • 1Service de Néphrologie Pédiatrique, Hôpital Necker-Enfants Malades, Université Paris-Descartes, Paris, France. pniaudet@gmail.com

Nephrologie & Therapeutique
|November 29, 2011
PubMed
Summary
This summary is machine-generated.

Renal transplant immunosuppression uses induction and maintenance therapies. New protocols aim to reduce side effects by lowering corticosteroid and calcineurin inhibitor doses in low-risk patients.

More Related Videos

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Related Experiment Videos

Last Updated: May 27, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients
18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Post-renal transplant immunosuppression is crucial to prevent rejection.
  • Initial induction therapy and long-term maintenance therapy are standard protocols.
  • Corticosteroids, antimetabolites, and calcineurin inhibitors are common maintenance agents.

Purpose of the Study:

  • To review current immunosuppressive strategies in renal transplantation.
  • To discuss the evolution of immunosuppressive protocols.
  • To highlight newer approaches focusing on side effect reduction.

Main Methods:

  • Review of immunosuppressive agents used in renal transplantation.
  • Analysis of induction and maintenance therapy protocols.
  • Examination of side effects and development of modified regimens.

Main Results:

  • Depleting anti-lymphocyte antibodies and anti-IL2 receptor antibodies are used for specific induction scenarios.
  • Maintenance therapy typically combines corticosteroids, antimetabolites (azathioprine, mycophenolate mofetil), and calcineurin inhibitors (cyclosporine, tacrolimus).
  • Newer protocols involve reducing or withdrawing corticosteroids and decreasing calcineurin inhibitor doses.

Conclusions:

  • Therapeutic adjustments are possible for patients at low immunological risk.
  • Reducing corticosteroid use addresses growth issues, while lower calcineurin inhibitor doses mitigate nephrotoxicity.
  • Optimizing immunosuppression balances efficacy with minimizing adverse effects in renal transplant recipients.